Recently, we reported the first case of donor-derived adult T-cell leukemia (ATL) after allogeneic stem cell transplantation (SCT) from a human T-cell leukemia virus type I (HTLV-I)-seropositive donor. 1 Southern blot analysis showed no significant clonal proliferation of HTLV-I-infected cells in the donor, and it remained unclear whether donor-derived ATL cells originated from T cells that were infected with HTLV-I in the donor. HTLV-I provirus load -the percentage of HTLV-I-infected cells among peripheral blood mononuclear cells (PBMCs) -was 1.3% in the donor, as most lymphocytes in asymptomatic carriers are not infected with HTLV-I. Accordingly, the donor-derived ATL may have developed in T cells that were newly infected with HTLV-I in the recipient after SCT. 2 As a follow-up to our earlier report, we have now demonstrated, using tumor-specific polymerase chain reaction (PCR) methods, that the HTLV-I-infected clone, which is identical to the donor-derived ATL cells, is present among PBMCs of the donor, indicating that the donor-derived ATL cells were infected with HTLV-I in the donor before SCT. The host immune-suppressive conditions involved in the development of donor-derived ATL, based on the expression of tax gene transcripts in the donor-derived ATL cells, are described below.
A 44-year-old Japanese man with refractory lymphoma-type ATL underwent SCT from his human leukocyte antigen (HLA)-identical, 40-year-old brother with HTLV-I infection in February 2004. The original tumor in the right side of the neck disappeared after SCT, but resumed growth 2 months later. After localized irradiation of 3060 cGy and rapid reduction of immunosuppressive agents, including cyclosporine and prednisone, the tumor once again disappeared. In July 2004, the clinical features of the recipient fulfilled the criteria of acutetype ATL, and the origin of the ATL cells was confirmed to be donor-derived based on the donor-recipient chimerism status determined by PCR studies using fluorescent primers flanking an informative microsatellite region. 1 In December 2006, the donor was still healthy.
The HTLV-I provirus is randomly integrated into host genomes, and thus integration sites of the HTLV-I provirus act as a landmark of specific HTLV-I-infected cells. We first identified integration sites of the HTLV-I provirus in the donorderived ATL cells by inverse long PCR. 3 After PstI digestion followed by circularization with T4 DNA ligase, genomic DNA extracted from the donor-derived ATL cells was amplified using the following opposite primers in the pX region: pX-F, 5 0 -TGGCACGCCTATGATTTCCG-3 0 and pX-R, 5 0 -GGGGGTTGT ATGAGTGATTG-3 0 (Figure 1a , open arrows). Inverse long PCR and sequencing studies showed that one copy of the HTLV-I provirus as a complete form was integrated into chromosome 21q22.2. On the basis of the genome sequence adjacent to the HTLV-I provirus, we established the PCR method designed to amplify the junction sequence between the 3 0 -long terminal repeat (LTR) of the HTLV-I provirus and the host genome.
In our previous experiment, we were unable to detect the donor-derived ATL clone by this tumor-specific PCR method. 2 To detect a small population of specific HTLV-I-infected clones among HTLV-I-infected cells, we changed the primer designs and PCR conditions. The following primers for tumor-specific PCR were designed in the 3'-LTR of the HTLV-I provirus and the flanking genome: U5-556F, 5
0 -TGCCTGACCCTGCTTGCTC AACTCTACGTCTTTG-3 0 ; TS-637R, 5 0 -CGCTAGGCCAGAGGT GACAACTGATGGTCC-3 0 ; and TS-320R, 5 0 -CAGGCATGTGC CACCATGTCCAATTGGCAG-3 0 ( Figure 1a , closed arrows). Semi-nested PCR was performed under the following conditions: 2 min at 951C for denaturation; 40 (1st PCR) or 25 (2nd PCR) cycles of 30 s at 951C, 30 s at 681C and 50 s at 721C; and 2 min at 721C for final extension. As a result, by the tumorspecific semi-nested PCR in the second round, we were able to successfully detect the donor-derived ATL clone among both recipient PBMCs at the onset of donor-derived ATL and donor PBMCs (Figure 1b) . In contrast, there was no such detection among PBMCs of another HTLV-I carrier.
The tumor-specific HTLV-I provirus load, the percentage of the donor-derived ATL clone among PBMCs, was quantified by tumor-specific real-time quantitative PCR methods using an ABI PRISM 7700 sequence detector system (PE Applied Biosystems, Foster City, CA, USA). We used the primers TS-F, 5 0 -ACAGCCCATCCTATAGCACTC-3 0 and TS-R, 5
0 -CGTCAG CAATGAAAATAACCC-3 0 , in combination with the TaqMan probe, 5 0 -CACACTTTTGGATCTGGTATCTTTCTCTC-3 0 . The HTLV-I provirus load in ATL cells -each of which contained one copy of the complete HTLV-I provirus -obtained from another patient with ATL was defined as 100%. Since most PBMCs were ATL cells at the onset of donor-derived ATL, we finally corrected the tumor-specific HTLV-I provirus load, assuming that the HTLV-I provirus load at the onset was equivalent to the percentage of the donor-derived ATL clone among PBMCs. To correct cell equivalents and PCR efficacy, recombination-activating gene 1 (RAG-1) was quantified by real-time PCR. The tumor-specific HTLV-I provirus load had already increased from 0 before SCT to 3.470.0% at engraftment (day 20), and it reached 97.870.7% at the onset (day 133). This period is very short for donor-derived HTLV-I-infected T cells to clonally expand, because ATL develops after an incubation period of approximately 60 years in Japan.
The HTLV-I viral protein Tax has a pivotal role in oligoclonal expansion of HTLV-I-infected T cells at an early stage after HTLV-I infection. On the other hand, cytotoxic T lymphocytes target Tax itself for the eradication of HTLV-I-infected cells, resulting in the suppression of ATL development and maintenance of the long carrier state. In 66% of ATL cases, the tax gene transcript could not be detected by reverse transcription (RT)-PCR, 4 and ATL cells without Tax expression are likely selected through an escape from the host immune surveillance during leukemogenesis. These findings suggest that ATL development requires inactivation of Tax by genetic mutations or epigenetic changes in the HTLV-I provirus. However, in our case of donor-derived ATL, the tax gene transcript could be detected by RT-PCR (Figure 2 ). The immunosuppressive state has been reported to potentially contribute to ATL development in HTLV-I carriers after liver transplantation. 5 In animal models, suppression of HTLV-I-specific cellular immune response also led to ATL development. 6 Taken together, the impaired immune response to viral antigens in the recipient might favor the malignant proliferation of HTLV-I-infected T cells that were controlled in the healthy carrier-donor with a normal immune system. Epstein-Barr virus (EBV)-associated posttransplant lymphoproliferative disorders (PTLDs) are well-established virusinduced lymphoid cancers that develop within 1 year after SCT under strong immunosuppressive conditions. 7 The impaired surveillance of T cells permits the polyclonal expansion of donor-derived EBV-infected B cells and eventually the outgrowth of a predominant clone. These clinical and biological features of EBV-associated PTLD closely resemble those of donor-derived ATL in our case. Therefore, donor-derived ATL may be a new category of virus-associated PTLD. Detection of the donor-derived ATL clone among PBMCs. (a) A flowchart of inverse long PCR and the structure of a PstI-digested fragment containing the pX region and the 3 0 -long terminal repeat (LTR) of the HTLV-I provirus and the flanking genome. Open and closed arrows indicate primer positions for inverse long PCR and tumor-specific PCR, respectively. (b) Genomic DNA from the recipient, donor and another HTLV-I asymptomatic carrier as a control -0.1, 500 and 500 ng, respectively -was amplified by tumor-specific PCR with U5-556F and TS-637R at 40 cycles in the first round and TS-320R at 25 cycles in the second round. As an internal control, the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene was amplified using 100 ng of genomic DNA each from the recipient, donor and the HTLV-I asymptomatic carrier. DW indicates distilled water used as a blank control. The limit of detection in this tumorspecific PCR was one donor ATL cell among 5 Â 10 3 PBMCs (data not shown).
Figure 2
Detection of the tax gene transcript in donor-derived ATL cells by RT-PCR. MT-1 and Jurkat cell lines were used as tax-positive and tax-negative controls, respectively. Total RNA obtained from the donor-derived ATL cells on day 164 after SCT was amplified with or without RT (the latter sample was used as a control template). The GAPDH gene transcript was used to confirm RNA integrity.
The median survival time with intensified chemotherapy was approximately 1 year in patients with aggressive ATL, including acute and lymphoma types. Allogeneic SCT promises to prolong survival in patients with aggressive ATL. 8 However, HLAmatched related donors are frequently infected with HTLV-I, because mother-to-child transmission by breast feeding is a major route of HTLV-I acquisition. Restricting the use of HTLV-Iseropositive donors deprives many patients with aggressive ATL of the chance to undergo SCT. On the other hand, among 10 patients with ATL who relapsed after SCT, three have achieved complete remission again by the reduction or cessation of immunosuppressive agents alone, which suggested a graftversus-ATL effect. 8 The use of HTLV-I-seropositive donors raises the concern of ATL development in donor-derived HTLV-Iinfected cells under immunosuppressive conditions after SCT, whereas it may enhance the therapeutic effect by the infusion of viral-specific immunocompetent cells.
In conclusion, our recent findings demonstrate that the HTLV-I-infected T cells that existed in the donor began to transform shortly after transplantation to the recipient. SCT from HTLV-Iseropositive donors involves the unknown risk of donor-derived ATL development, because the origin of relapsing ATL cells after SCT has not been extensively studied. Until the incidence of donor-derived ATL becomes clear, the use of HTLV-I-seropositive donors should be carefully considered for patients with aggressive ATL who are not curable by chemotherapy alone.
Effect of spacing intravenous bisphosphonates in patients with multiple myeloma in plateau phase Leukemia (2007) showed that patients with stage II or III MM, and at least one osteolytic lesion benefit from BP therapy administered monthly for 24 months. However, the benefit of prolonging BP treatment beyond 24 months is not clear. Ali et al. 3 studied the effects of long-term BP administration for up to 6 years, and showed that bone events can occur following 2 years of treatment and that the tolerance is generally good. However, osteonecrosis of the jaw has been reported recently as a severe dose and time-dependent related adverse effect. 4 The Mayo Clinic has recently published a consensus for the use of BP in MM, proposing, after 2 years of treatment, to decrease the rate of BP injections from one per month to one every 3 months Figure 1 Event-free survival of BP1 and BP3 patients. Event-free survival was defined as the time in months between the study entry and an event (a skeletal event or myeloma progression). The occurrence of events was estimated according to the Kaplan-Meier method, and the log-rank test was performed to compare BP1 and BP3 patients (P ¼ 0.82).
